National Action Plan on Antimicrobial Resistance (NAP-AMR 2.0)
Table of Contents
Source: The Hindu
Relevance: Facts for Prelims, GS Paper – 2 – Government Policies & Interventions, GS Paper – 3 – Health
Important Key Concepts for Prelims and Mains:
For Prelims:
- Antimicrobial resistance, Superbugs, Schedule H1, NDM-1 (New Delhi Metallo-beta-lactamase), Red Line Campaign, E. coli, Klebsiella and Pseudomonas.
For Mains:
- Factors Fueling the Growing AMR Crisis in India, Measures that can be Adopted to Effectively Counter AMR Crises in India
Why in News?
- Government has launched National Action Plan on Antimicrobial Resistance (NAP-AMR 2.0, 2025-29).
- Article argues that its success depends on strong Centre–State coordination; otherwise, it may remain only a “technical document”.
What is Antimicrobial Resistance (AMR)
- Definition: When microorganisms (bacteria, viruses, fungi, parasites) stop responding to medicines that once killed them.
- Leads to “superbugs” – pathogens resistant to multiple drugs → routine infections become hard or impossible to treat.
How Microbes Become Resistant (Mechanisms)
- Limiting uptake – alter cell wall, drug can’t enter.
- Target modification – change the molecule the drug binds to.
- Efflux pumps – “pumps” that throw the drug out of the cell.
- Drug inactivation – enzymes (e.g. β-lactamases) that destroy the drug.
One Health Framework
- Recognises that human, animal and environmental health are interconnected.
- AMR spreads via hospitals, farms, aquaculture, soil, sewage, rivers, food chains, markets – not just clinics.
Background / Present Status
- Silent pandemic & development threat: AMR now threatens decades of gains in health, agriculture & poverty reduction.
- India faces AMR across:
- Hospitals & ICUs,
- Livestock & aquaculture,
- Pharma manufacturing hubs (e.g. Musi River, Hyderabad),
- Poor sanitation & untreated sewage.
- Economic & social stakes:
- Treatment of resistant infections requires costly “last-resort” drugs (e.g. colistin, meropenem), long hospital stays and isolation → huge OOPE (39.4% of Total Health Expenditure).
- Resistant neonatal sepsis kills tens of thousands of newborns annually, undermining IMR goals.
- World Bank estimates up to 3.8% global GDP loss by 2050 due to AMR; India, as a high-burden country, is especially vulnerable.
Important Terms
- Superbugs: Multi-drug-resistant organisms (e.g. carbapenem-resistant E. coli, Klebsiella, Pseudomonas).
- NDM-1 (New Delhi Metallo-β-lactamase): Enzyme that makes bacteria resistant to powerful β-lactam antibiotics (incl. carbapenems).
- Schedule H1: Drugs & Cosmetics Rules category; select antibiotics can be sold only on prescription, with pharmacy register & record-keeping.
- Red Line Campaign: Red vertical line printed on antibiotic strips → “use only with doctor’s prescription” awareness tool.
What is NAP-AMR 1.0 & 2.0?
NAP-AMR 1.0 (2017) – Achievements & Limits
- Achievements
- Put AMR on national agenda; adopted explicit One Health framing.
- Expanded lab networks, surveillance (ICMR-AMRSN, NCDC networks).
- Promoted antibiotic stewardship & multi-sectoral participation.
- Limitations
- Weak State-level implementation:
- Only a few States (Kerala, MP, Delhi, AP, Gujarat, Sikkim, Punjab) prepared formal State AMR Action Plans, fewer executed them well.
- Most States continued with fragmented, sector-specific efforts, no functional One Health structure.
- Root cause: key levers of AMR (health services, pharmacy control, livestock, agriculture, food safety, waste regulation) lie within State jurisdiction; national guidance alone could not ensure implementation.
- Weak State-level implementation:
NAP-AMR 2.0 (2025–29) – Key Features
- More implementation-oriented: Clearer timelines, responsibilities & resource planning.
- Strengthened One Health:
- Greater focus on food-systems, waste management & environmental contamination.
- Integrated surveillance across human, veterinary, agriculture & environment.
- Innovation push: Emphasis on rapid diagnostics, point-of-care tools, alternatives to antibiotics, better environmental monitoring.
- Private sector engagement: Recognises that private hospitals & vets provide a large share of care; seeks their participation.
- Governance:
- Inter-sectoral supervision under NITI Aayog via a Coordination & Monitoring Committee.
- Urges all States/UTs to set up State AMR Cells & State Plans; proposes a national dashboard.
- Significance: Elevates AMR from a clinical issue to a national development priority.
Core Weakness of NAP-AMR 2.0
- No binding Centre–State implementation mechanism:
- No statutory requirement for States to notify plans or establish AMR Cells.
- No regular joint review missions, no formal Centre–State AMR council, no NHM-linked financial incentives.
- In a federal system where most determinants of AMR are State subjects, this is the “pivotal gap” → risk that NAP-AMR 2.0 stays a well-written document, not a live programme.
Factors Fueling the AMR Crisis in India
Clinical Misuse & “Pill-Popping Culture”
- Broad-spectrum antibiotics prescribed for viral fevers due to lack of rapid diagnostics & patient expectations.
- Schedule H1 enforcement is patchy; many pharmacies still sell strong antibiotics OTC.
- Massive use of “Watch”-group antibiotics (≈59% of consumption, 2022); ~8 in 10 hospital entrants carry drug-resistant bacteria.
- Post-COVID, habit of casually taking Dolo-650 etc. symbolises this mindset.
Livestock & Aquaculture Misuse (Growth-Promoter Epidemic)
- Poultry & shrimp industries use critical drugs like colistin as growth promoters, not for treatment.
- India is 4th largest animal-antibiotic consumer; use projected to rise ~82% by 2030.
- Studies show 100% resistance to ampicillin in some shrimp samples from Kerala retail markets.
Pharmaceutical Pollution – “Hyderabad Model”
- Untreated effluents from pharma hubs discharge high levels of active antibiotics into rivers (e.g. Musi River antibiotic levels ~1,000× safe limits).
- These act as “evolutionary pressure cookers”, forcing bacteria to mutate into superbugs that spread through groundwater, irrigation and drinking water.
Irrational Fixed-Dose Combinations (FDCs)
- Many unscientific “cocktail” drugs (multiple antibiotics, or antibiotic + vitamin) lead to sub-therapeutic exposure, speeding resistance.
- Govt banned 156 FDCs in 2024 (including antibiotic cocktails) for “no therapeutic justification”, but others still circulate.
Sanitation & Wastewater Failures – “Scavenger Spread”
- Poor sewage treatment lets resistant organisms like NDM-1-producing E. coli, Klebsiella, Pseudomonas leave hospitals and colonise municipal water.
- Flawed toilet/sewage networks recycle these back into households, creating a continuous transmission loop.
Surveillance & Diagnostic Gaps
- Data mainly from public tertiary hospitals & ICUs (ICMR-AMRSN, NARS-Net); rural & primary-care settings are blind spots.
- Lack of affordable rapid tests → doctors prescribe empirically for safety → over-prescription.
Threats Posed by AMR
(A) Economic
- Export & Trade Losses
- Seafood & shrimp exports face rejections in EU/US due to antibiotic residues.
- Poultry may be excluded from “antibiotic-free” global value chains.
- Healthcare Cost Explosion & Poverty
- Resistant infections need costly drugs & long hospital stays.
- With 39.4% OOPE, one episode of resistant sepsis can impoverish families.
- Productivity & GDP Loss
- Working-age population suffers prolonged illness; absenteeism rises.
- AMR could shave off up to 3.8% of global GDP by 2050; India’s demographic dividend is at risk.
(B) Social & Public Health
- Return to Pre-Antibiotic Era
- Routine surgeries (C-sections, joint replacements, chemo) become high-risk.
- ~50,000+ newborn deaths/year from resistant sepsis undermine IMR targets.
- Hospital Superbugs & MDR-TB
- Carbapenem-resistant E. coli, Klebsiella etc. now common in ICUs → almost no drugs left.
- India has highest MDR-TB burden; airborne, chronic and poverty-reinforcing.
(C) Environmental
- Pharma effluents & agricultural run-off contaminate rivers, soil & groundwater with antibiotics and resistant organisms → classic One Health crisis.
Indian Government & Policy Response
- NAP-AMR 1.0 (2017) and NAP-AMR 2.0 (2025-29) – national frameworks adopting One Health, surveillance & stewardship.
- Delhi Declaration on AMR (2017) – inter-ministerial commitment.
- Chennai Declaration – professional consensus of Indian medical societies on rational antibiotic use.
- Schedule H1 – restricts sale of selected antibiotics; pharmacies must keep records.
- Red Line Campaign – visible red line on antibiotic strips to discourage OTC use.
- Ban on colistin in animal feed (critical last-resort drug).
- FDC Ban (2024) – 156 irrational antibiotic combinations prohibited.
- ICMR-AMRSN (2013) – national AMR surveillance across tertiary hospitals.
- State innovations: e.g. Kerala’s PROUD & AMRITH initiatives, strict OTC enforcement, One-Health coordination.
What Must Be Done – Way Forward
Strengthen NAP-AMR 2.0 via Cooperative Federalism
- National–State AMR Council
- Chaired by Union Health Minister + NITI Aayog; includes key State ministers & secretaries (health, animal husbandry, agriculture, environment).
- Platform for joint reviews, problem-solving and sharing best practices.
- Mandatory State AMR Action Plans & Cells
- Formal letters from GoI / Chief Secretaries; notification with timelines & annual review.
- NHM-Linked Conditional Grants
- Earmarked funds for labs, surveillance, infection prevention, stewardship & WASH; funding signals priority.
- Integrated One-Health Dashboard
- Legally mandated data from human, veterinary, environment sectors; AI-based detection of “hotspots” linking farm antibiotic use with human outbreaks.
Fix Human-Health Drivers
- Hub-and-Spoke Diagnostic Grid
- Tertiary-care labs as Hubs, PHCs/CHCs as Spokes.
- Samples transported with cold chain; digital antibiogram reports within 24 hrs → reduces blind prescriptions.
- Promote low-cost rapid tests (Assam’s DOSA, IIT lab-on-chip, etc.) to distinguish viral vs bacterial infections.
- Behaviour Change Communication (BCC)
- Move beyond posters: use teachers, religious leaders, ASHAs to frame antibiotics as “precious, limited weapons”.
- Normalise that not every fever needs antibiotics; rest & time often suffice.
- “Blue Envelope Protocol” for Antibiotics
- All antibiotic strips dispensed only in a distinct blue envelope with message: “Complete full course; incomplete doses create superbugs.”
- Makes antibiotics psychologically distinct from routine pills and discourages storage for casual future use.
Address Animal, Food & Environment Pathways
- “Antibiotic-Smart Villages / WASH-First Defence”
- 100% clean water, toilets, sewage treatment in pilot clusters → reduced diarrhoea & typhoid → lower antibiotic demand.
- Green-Pharma Procurement
- Govt tenders to favour companies with Zero Liquid Discharge (ZLD) and real effluent treatment → profits tied to clean production.
- Farm-to-Fork Traceability (Poultry & Aquaculture)
- Blockchain / QR-code system that records feed, vaccines, and antibiotic-use history; consumers can see if meat/eggs are “antibiotic-free” → pushes industry towards safer practices.
- Subsidised Animal Vaccines & Better Biosecurity
- Vaccinating poultry & livestock significantly cuts disease → fewer antibiotics used.
- Kerala-Style Enforcement Nationwide
- Strict ban on OTC sale of antibiotics + regular inspections; multi-sectoral One Health committees at district level.
Conclusion
AMR is not just a medical issue; it is a multi-dimensional development crisis that threatens food security, exports, public health and India’s demographic dividend. India has taken bold steps — from banning colistin and irrational FDCs to launching NAP-AMR 2.0 under a One Health framework. But without hard Centre–State coordination, sustained funding, and behaviour change from wards to farms to factories, these measures will fall short.
If India can now build a coordinated, accountable, One-Health implementation architecture, it can both protect its people and emerge as a global leader in the fight against superbugs. If not, we risk sliding back into a pre-antibiotic era where routine infections once again become potential death sentences.
UPSC PYQ
Which of the following are the reasons for the occurrence of multi-drug resistance in microbial pathogens in India? (2019)
- Genetic predisposition of some people
- Taking incorrect doses of antibiotics to cure diseases
- Using antibiotics in livestock farming
- Multiple chronic diseases in some people
Select the correct answer using the code given below.
(a) 1 and 2
(b) 2 and 3 only
(c) 1, 3 and 4
(d) 2, 3 and 4
Ans: (b)
CARE MCQ
Q. Consider the following sectors:
- Pharmaceutical manufacturing
- Livestock and aquaculture
- Wastewater and sanitation systems
- Intensive Care Units (ICUs)
In the context of India’s AMR challenge, which of the above are recognised as major “primary drivers” in NAP-AMR 2.0’s One Health framework?
A. 1, 2 and 3 only
B. 1 and 4 only
C. 2, 3 and 4 only
D. 1, 2, 3 and 4
Answer: A
Explanation:
NAP-AMR 2.0 identifies pharma pollution, livestock overuse, and wastewater contamination as primary community-level drivers of AMR. ICU resistance emerges downstream; the main drivers occur outside hospitals.
